title: The beta 2-adrenergic agonist terbutaline suppresses acute passive transfer experimental autoimmune myasthenia gravis (EAMG).
abstract: Treatment of Lewis rats with the beta 2-adrenergic agonist terbutaline suppressed clinical symptoms of acute passive transfer EAMG induced with monoclonal anti-acetylcholine receptor antibody and accelerated clinical recovery in affected animals. Electrophysiological studies showed that the amplitude of the first compound muscle action potential was significantly larger in terbutaline-treated rats as compared to controls. In both groups, a comparable number of inflammatory cells at the muscle endplates was seen.
authors.affiliation: Department of Neurology, University of Chicago, IL 60637.
authors.forename: E
authors.initials: E
authors.lastname: Chelmicka-Schorr
authors.forename: R L
authors.initials: RL
authors.lastname: Wollmann
authors.forename: M N
authors.initials: MN
authors.lastname: Kwasniewski
authors.forename: D H
authors.initials: DH
authors.lastname: Kim
authors.forename: B L
authors.initials: BL
authors.lastname: Dupont
mesh_terms: D000208:Acute Disease; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D004576:Electromyography; D005260:Female; D007116:Immunization, Passive; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D009045:Motor Endplate / Q000276:immunology / Q000473:pathology; D009157:Myasthenia Gravis / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D011917:Rats, Inbred Lew; D013726:Terbutaline / Q000494:pharmacology*
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D013726:Terbutaline